Cellectar Biosciences Inc

詳細情報 Cellectar Biosciences Inc 企業名

Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).

企業情報

企業コードCLRB

会社名Cellectar Biosciences Inc

上場日May 20, 2005

最高経営責任者「CEO」Mr. James V. Caruso

従業員数11

証券種類Ordinary Share

決算期末May 20

本社所在地100 Campus Drive

都市FLORHAM PARK

証券取引所NASDAQ Capital Market Consolidated

国United States of America

郵便番号07932

電話番号16084418120

ウェブサイトhttps://www.cellectar.com/

企業コードCLRB

上場日May 20, 2005

最高経営責任者「CEO」Mr. James V. Caruso

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Jarrod Longcor

Chief Operating Officer

12.77K

+360.88%

Mr. James V. Caruso

President, Chief Executive Officer, Director

11.64K

+609.38%

Mr. Chad J. Kolean

Chief Financial Officer, Vice President, Secretary

6.42K

+352.36%

Mr. Douglas J. (Doug) Swirsky

Independent Chairman of the Board

83.00

--

Mr. Stefan D. Loren, Ph.D.

Independent Director

--

Mr. Frederick W. (Fred) Driscoll

Independent Director

--

Mr. John P. Neis

Independent Director

--

Dr. Asher Alban Chanan-Khan, M.D.

Independent Director

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Jarrod Longcor

Chief Operating Officer

12.77K

+360.88%

Mr. James V. Caruso

President, Chief Executive Officer, Director

11.64K

+609.38%

Mr. Chad J. Kolean

Chief Financial Officer, Vice President, Secretary

6.42K

+352.36%

Mr. Douglas J. (Doug) Swirsky

Independent Chairman of the Board

83.00

--

Mr. Stefan D. Loren, Ph.D.

Independent Director

--

Mr. Frederick W. (Fred) Driscoll

Independent Director

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Sat, Sep 6

株主統計

種類

株主統計

比率

Hexstone Capital LLC

4.70%

The Vanguard Group, Inc.

1.76%

Geode Capital Management, L.L.C.

0.45%

Longcor (Jarrod)

0.40%

HRT Financial LP

0.39%

他の

92.29%

株主統計

比率

Hexstone Capital LLC

4.70%

The Vanguard Group, Inc.

1.76%

Geode Capital Management, L.L.C.

0.45%

Longcor (Jarrod)

0.40%

HRT Financial LP

0.39%

他の

92.29%

種類

株主統計

比率

Corporation

5.00%

Investment Advisor

2.74%

Individual Investor

1.07%

Investment Advisor/Hedge Fund

0.60%

Hedge Fund

0.04%

Bank and Trust

0.04%

Research Firm

0.01%

他の

90.49%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

84

195.80K

7.48%

-354.58K

2025Q1

86

199.12K

11.22%

-346.61K

2024Q4

85

5.89M

13.20%

-10.24M

2024Q3

82

15.21M

37.53%

+860.01K

2024Q2

87

12.77M

37.42%

+1.31M

2024Q1

84

10.31M

32.95%

-1.69M

2023Q4

71

9.17M

43.97%

+2.46M

2023Q3

74

3.14M

32.62%

+389.97K

2023Q2

83

3.71M

38.83%

+394.07K

2023Q1

91

3.81M

40.21%

+165.83K

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

The Vanguard Group, Inc.

57.40K

2.14%

-172.00

-0.30%

Mar 31, 2025

Geode Capital Management, L.L.C.

14.78K

0.55%

+3.08K

+26.38%

Mar 31, 2025

Longcor (Jarrod)

2.77K

0.18%

+1.00K

+56.47%

Apr 17, 2025

HRT Financial LP

1.54K

0.06%

+1.54K

--

Mar 31, 2025

Caruso (James V)

1.64K

0.11%

--

Apr 17, 2025

BlackRock Institutional Trust Company, N.A.

7.46K

0.28%

-56.00

-0.75%

Mar 31, 2025

詳細を見る

5.200USD

Cellectar Biosciences Inc

5.200

概要

企業名

金融

分析